Improving Patient Education and Reducing Risk

Formulary Update

The following actions were taken by the Pharmacy and Therapeutics Committee at their meeting on 6/22/01:

1. Bismuth subgallate epinephrine (BSE) paste, a compounded topical hemostatic agent, was added to the Formulary for the control of bleeding after adenotonsillectomy.

2. Tolterodine LA (Detrol LA^®) was added to the Formulary for the control of overactive bladder. Oxybutynin XL (Ditropan XL^®) was rejected.

3. A request for the addition of a leuprolide acetate implant (Viadur^®) was rejected because the product lacks significant advantages over the 4 month depot injection.

4. Valganciclovir (Valcyte^®) was added for the management of CMV retinitis.

Pediatr Pharm. 2001;7(7) © 2001 Children's Medical Center, University of Virginia